Company: DVAX
Filing Date: 2025-02-07
Form Type: 8-K
Source: 0001029142-25-000016
Chunk: 0

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-02-07
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 3, 2025

There will be no change in Ms. MacDonald’s compensation as a result of this appointment. Biographical information for Ms. MacDonald is available in the Company’s proxy statement filed with the Securities and Exchange Commission on April 11, 2024 in connection with the Company’s 2024 annual meeting of stockholders, such information being incorporated herein by reference.

There are no arrangements or understandings between Ms. MacDonald and any other persons in connection with Ms. MacDonald’s appointment as a principal accounting officer. There are also no family relationships between Ms. MacDonald and any director or executive officer of the Company and Ms. MacDonald has no direct or indirect interest in any transaction or proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

                                            Dynavax Technologies Corporation  
  Date:      February 7, 2025      By:      /s/ RYAN SPENCER                  
                                            Ryan Spencer